[Therapy of hormone refractory prostate cancer: new standards, new trends]. [electronic resource]
Producer: 20060623Description: 342-8 p. digitalISSN:- 0001-7868
- Angiogenesis Inhibitors -- administration & dosage
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Agents, Hormonal -- therapeutic use
- Antineoplastic Agents, Phytogenic -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Clinical Trials, Phase I as Topic
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Diphosphonates -- administration & dosage
- Docetaxel
- Drug Resistance, Neoplasm
- Endothelin Receptor Antagonists
- Humans
- Male
- Meta-Analysis as Topic
- Mitoxantrone -- administration & dosage
- Mutation
- Oligonucleotides, Antisense -- therapeutic use
- Patient Selection
- Prostatic Neoplasms -- drug therapy
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Quality of Life
- Randomized Controlled Trials as Topic
- Receptors, Androgen -- genetics
- Taxoids -- administration & dosage
- Time Factors
- Trastuzumab
No physical items for this record
Publication Type: Comparative Study; Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.